Core Viewpoint - Kweichow Moutai's subsidiary Harbin Kweichow Moutai Pharmaceutical Co., Ltd. has received a notice of acceptance for the registration application of "Yihuo Probiotic Powder" from the State Administration for Market Regulation, indicating potential health benefits related to immune enhancement and bowel regulation [1] Group 1 - The product "Yihuo Probiotic Powder" has undergone animal testing and has been evaluated for its health functions [1] - The product is positioned to assist in enhancing immunity and promoting bowel movement [1]

Market Overview - The S&P 500 index briefly crossed 7000 points for the first time on January 28, 2026, rebounding nearly 40% since April 2025 lows, with five record closes noted by January 27, 2026 [1] - The Nasdaq Composite has seen modest gains in 2026, while the Russell 2000 has surged nearly 7% year-to-date as of January 29, 2026, outperforming large-cap peers for 14 consecutive trading sessions, the longest streak since 1996 [2] Valuation Concerns - The Shiller S&P 500 price-to-earnings ratio is currently at 41, the highest since the dot-com bubble, while the trailing P/E ratio is at 31.52, significantly above the historical average of 16.2 [3] - Bank of America's head of US equity strategy, Savita Subramanian, indicates that the S&P 500 is expensive, predicting it will reach 7,100 by year-end 2026, which is among the lowest forecasts on Wall Street [3] Investment Strategy - Goldman Sachs analysts predict that value stocks will remain favored if US economic momentum strengthens, noting that these stocks, with forward P/E ratios below 15, have outperformed higher-valuation stocks at the start of the year, achieving a 15% return in the last six months of 2025 [4] Stock Selection Methodology - The list of best cheap stocks for 2026 was created using screeners like TradingView and Finviz, focusing on US-listed stocks with forward P/E ratios between 3 and 15 and a positive upside potential of at least 20%, ranked by hedge fund holdings as of Q3 2025 [7][8] HNI Corporation - HNI Corporation (NYSE:HNI) is highlighted as a top cheap stock for 2026, with a forward P/E of 11.92 and an upside potential of 58.46% [9] - Benchmark Co. raised its price target for HNI to $75 per share from $60, citing a planned acquisition of Steelcase Inc. valued at approximately $2.2 billion, expected to yield annual cost synergies of about $120 million [10] - HNI's shares are priced below historical values, with a P/E ratio of 13.35, and the company has a history of consistent dividend payments over 55 years [11] Sanofi SA - Sanofi SA (NASDAQ:SNY) is also listed as a cheap stock for 2026, with a forward P/E of 9.02 and an upside potential of 25.11% [15] - Citi Research initiated coverage on Sanofi with a Neutral rating and an €85 price target, expressing concerns over pipeline setbacks affecting long-term growth [16] - Sanofi's current valuation reflects these setbacks, with analysts noting that the market is unlikely to reward the stock with a higher multiple without evidence of pipeline improvement [17] - Positive results were reported for Sanofi's experimental medicine amlitelimab in Phase 3 clinical studies for atopic dermatitis, indicating potential for future growth [18]

Core Viewpoint - CROSSJECT, a specialty pharmaceutical company, has announced the initiation of stock coverage by Portzamparc (BNP Paribas Group) with a "Strong Buy" recommendation and a target price of €4.50 [1]. Company Overview - CROSSJECT is developing emergency medicines utilizing its ZENEO® needle-free auto-injector technology, which allows for easy and instant delivery of drugs [2]. - The company is in advanced regulatory development for ZEPIZURE®, an injectable treatment for epileptic seizures, supported by a $60 million contract with BARDA [2][3]. - Other products in development include solutions for allergic shocks, adrenal insufficiencies, and various emergency indications [2].

Group 1 - The core point of the article is that French drugmaker Sanofi's experimental treatment for a genetic disorder shows promise in a late-stage study for Gaucher disease, but did not meet the main goal in a separate trial [1] Group 2 - The treatment demonstrated potential effectiveness in patients with a specific type of Gaucher disease during the late-stage study [1] - However, the results from another trial did not achieve the primary endpoint, indicating challenges in the development process [1]

Group 1 - Pfizer Inc. is set to release its fourth-quarter earnings results on February 3, with analysts expecting earnings of 57 cents per share, a decrease from 63 cents per share in the same period last year [1] - The consensus estimate for Pfizer's quarterly revenue is $16.83 billion, down from $17.76 billion a year earlier [1] Group 2 - Novavax, Inc. announced a license agreement with Pfizer for the use of its Matrix-M adjuvant on January 20 [2] - Following the announcement, Pfizer's shares increased by 1.4%, closing at $26.44 [2]

Core Insights - Sanofi's investigational drug venglustat has shown positive results in a phase 3 study for type 3 Gaucher disease, meeting all primary endpoints and three out of four key secondary endpoints [1][4][8] Group 1: Study Results - The LEAP2MONO phase 3 study demonstrated that patients receiving venglustat had statistically significant improvements in neurological symptoms compared to those receiving enzyme replacement therapy (ERT), with a p-value of 0.007 [4][8] - Venglustat showed comparable efficacy to ERT in non-neurological outcomes, including changes in spleen volume, liver volume, and hemoglobin levels [4][8] - The study involved 43 patients aged 12 and older, randomized to receive either venglustat or ERT, with a focus on neurological assessments over 52 weeks [13] Group 2: Drug Mechanism and Background - Venglustat is a glucosylceramide synthase inhibitor designed to reduce the accumulation of harmful sugar-and-fat molecules in cells, specifically targeting neurological aspects of Gaucher disease that lack approved therapies [2][12] - Gaucher disease is a rare lysosomal storage disorder characterized by the accumulation of glycosphingolipids, leading to various systemic and neurological symptoms [10] Group 3: Future Plans and Regulatory Path - Sanofi plans to pursue global regulatory filings for venglustat in treating type 3 Gaucher disease [7][8] - The company has a long-standing commitment to rare disease research and has supported the Gaucher disease community for over 40 years [2][4] Group 4: Safety and Tolerability - Venglustat was well tolerated in the study, with no new safety signals reported compared to previous studies; common adverse events included headache, nausea, spleen enlargement, and diarrhea [6][8]

Core Viewpoint - Levi & Korsinsky has initiated an investigation into Aquestive Therapeutics, Inc. for potential violations of federal securities laws following the FDA's identification of deficiencies in its NDA application for Anaphylm, impacting the company's stock price significantly [1][2]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is facing scrutiny after receiving a letter from the FDA on January 9, 2026, which highlighted deficiencies in its NDA application that prevent further discussions on labeling and post-market commitments for its product Anaphylm, intended for emergency treatment of anaphylaxis [1]. - Following the FDA's announcement, Aquestive's stock price dropped by $2.18, representing a 35.1% decline, opening at $4.03 [2]. Group 2: Legal and Financial Implications - The investigation by Levi & Korsinsky is aimed at exploring potential recovery options for investors who may have suffered losses due to the recent developments concerning Aquestive Therapeutics [2]. - Levi & Korsinsky LLP has a strong reputation in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years, and is recognized as one of the top securities litigation firms in the United States [3].

Group 1 - The core viewpoint is that AI is accelerating the transformation of the healthcare industry, with significant growth potential in companies like Huaxi Biological, which expects a net profit increase of 54.93%-83.63% by 2025 [1] - Huaxi Biological's stock led the gains in the Sci-Tech Innovation Board, rising by 7.70%, indicating strong market interest and confidence in its future performance [1] - The Sci-Tech 100 ETF has shown significant liquidity and growth, with a recent trading volume of 1.74 billion yuan and a 1.32 billion yuan increase in scale over the past two weeks [1] Group 2 - According to Everbright Securities, AI has become a core productivity driver in the new infrastructure of healthcare, with AI drug development and AI medical imaging being the most mature sectors [2] - The future competition in the AI healthcare space will focus on exclusive high-quality private data and the ability to create closed-loop business scenarios [2] - The Sci-Tech 100 ETF closely tracks the Sci-Tech 100 Index, which focuses on high-growth sectors including semiconductors, pharmaceuticals, and new energy [2]

MNC押注超长效多肽药物，角逐减重与代谢大市场 2025年11月，辉瑞经过与诺和诺德激烈竞价最终以100亿美元对价实现对减肥药研发企业Metsera的收 购，Metsera基于其专有NuSH平台实现了MET-097(GLP-1，临床II期)的超长半衰期，使其具备每月注射 一次的药代动力学基础。而公司SYH2082是一款正推进至临床I期的每月一次注射长效GLP1R/GIP激动 剂，该行期待有更多优异疗效和安全性数据读出。 对外授权持续兑现，有望形成常态化收入 2025年公司已实现口服小分子GLP-1(1.2亿美元首付款)、阿斯利康战略合作(1.1亿美元预付款)、伊利替 康脂质体(1500万美元首付款)、ROR1ADC(1500万美元首付款)的对外授权。公司研发管线中还有EGFR ADC/SiRNA系列等进度领先的创新资产，该行期待有望持续实现对外授权落地和更多里程碑收入确 认。 中金发布研报称，维持石药集团(01093)"跑赢行业"评级，考虑对外授权持续兑现上调目标价9.1%到12 港元。该行维持公司25/26年盈利预测47.60亿元/53.53亿元，引入2027年56.95亿元预期。石药集团公告 与阿斯利康签 ...

Group 1: Economic Indicators - Economists expect nonfarm payrolls to rise by 68K last month, with the unemployment rate remaining steady at 4.4% [3] - The upcoming jobs numbers may be overshadowed by comments from Fed-chair nominee Kevin Warsh regarding interest rates [3][4] Group 2: Earnings Reports - Amazon is projected to report EPS of $1.94 on revenue of $211 billion, with analysts anticipating an upside surprise due to AWS capacity additions and AI infrastructure demand [5] - Alphabet is set to report earnings on Wednesday, while Amazon will follow on Thursday, highlighting the focus on megacap companies this week [5][6] Group 3: Industry Trends - Amazon's recent layoffs, approximately 10% of its corporate workforce, are seen as a shift towards AI-driven operations, reflecting a broader trend in Big Tech [6] - The labor market may face deterioration as companies increasingly adopt AI, potentially leading to more layoffs and reduced hiring [4] Group 4: Cryptocurrency Market - Bitcoin has dipped below $80K, marking its lowest level since April 2025, and has experienced a fourth consecutive monthly decline [8] - The total cryptocurrency market cap has decreased by about 4%, falling below $2.8 trillion, with Bitcoin now ranking as the 12th-largest asset by market cap [9]